We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Elixir licenses rights to BMS's growth hormone stimulant
19 May 2009
Executive Summary
Seeking to become a fully integrated biopharmaceutical company, Elixir, which develops drugs for diseases related to aging, has licensed exclusive worldwide development and commercialization rights to Bristol-Myers Squibb's ghrelin agonist BMS-604992 (later called, EX1314, it stimulates appetite, gastric motility, and the release of growth hormone). and five related compounds to treat metabolic disorders.
Deal Industry
Pharmaceuticals
Biotechnology
Large Molecule
Deal Status
Final
Deal Type
Alliance
Includes Equity
R&D and Marketing (Licensing)
Reverse Licensing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?